In a report published Friday, Wedbush Securities analyst Heather Behanna assumed coverage on Noravax NVAX with an Outperform rating and $10.00 price target, down from $12.00.
In the report, Wedbush Securities noted, “Novavax's analyst day next week should provide clarity on timelines for abusy 2015. Novavax is gearing up for three trials for its RSV vaccine program by year end; it has begun a proof-of-concept study for maternal immunization and will initiate studies in both pediatric and elderly populations. A dose confirmation study of its retooled quadrivalent flu vaccine will also be initiated this year; all four studies should read out data in 2015, driving value for Novavax.”
Noravax closed on Thursday at $4.59.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in